Atara Biotherapeutics beat earnings estimates in Q3 2025 despite a loss, as its lead therapy advanced in late-stage trials.

Atara Biotherapeutics reported a third-quarter 2025 loss of $0.32 per share, beating estimates by $0.51, with $3.5 million in revenue. The company’s lead therapy, Tab-cel, advanced in Phase 3 trials for EBV-related post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. Despite a negative return on equity and net margin, the stock rose slightly, closing at $12.23, with institutional investors holding 70.9% of shares. Weiss Ratings downgraded the stock to “sell,” but analysts maintain a “moderate buy” consensus with a $21 target.